Financial Data and Key Metrics Changes - Operating revenues surpassed $2,000,000,000 for the first time, reaching $2,020,000,000, which is a 14% increase in constant currency [34][13] - Net profit after tax was $377,200,000, reflecting a 30% increase in constant currency compared to the previous year [34][13] - Gross margin improved to 62.9%, an increase of 1.3% in constant currency [36] Business Line Data and Key Metrics Changes - Hospital business revenue was $1,280,000,000, up 16% in constant currency [34] - Home care business revenue reached $739,900,000, an 11% increase in constant currency [34] Market Data and Key Metrics Changes - The company’s products were used to treat 22 million patients in FY 2025, indicating strong market demand [30] - The manufacturing facility in China became fully operational, contributing to sales [31] Company Strategy and Development Direction - The company focuses on long-term planning, with a perspective extending beyond 15 years, guiding R&D and infrastructure investments [6][8] - Infrastructure investments include the construction of a fifth building at the East Tamaki campus and securing land for a second campus in New Zealand [8][7] - The company aims to double its revenue every five to six years sustainably [60] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the impact of global geopolitics and tariffs but emphasized a long-term strategy to mitigate cost increases through continuous improvements [9][12] - The outlook for FY 2026 anticipates revenue between $2,150,000,000 and $2,250,000,000, with net profit after tax expected to be between $390,000,000 and $440,000,000 [56] Other Important Information - The company is committed to maintaining a prudent balance sheet while investing in R&D and global sales [14] - The board approved a 2% increase in dividends, totaling $0.0425 per share, representing a payout ratio of about 66% [13][14] Q&A Session Summary Question: Why hasn't the company conducted a major investor day like Xero? - The company complies with New Zealand regulations and believes its disclosures are adequate, thus not planning to adopt the Australian remuneration report [66] Question: What are the expectations for FY 2026 underlying profit? - Management referred to the outlook provided earlier, indicating a long-term growth trajectory despite fluctuations during the COVID period [68] Question: How many shareholders voted in favor of the CEO's reelection? - The number of votes will be disclosed at the end of the meeting, but the focus will be on the number of votes rather than individual shareholders [84]

Financial Data and Key Metrics Changes - Operating revenues surpassed $2,000,000,000 for the first time, reaching $2,020,000,000, which is a 14% increase in constant currency [31][32] - Net profit after tax was $377,200,000, reflecting a 30% increase in constant currency compared to the previous year [12][32] - Gross margin improved to 62.9%, an increase of 1.3% in constant currency [34] Business Line Data and Key Metrics Changes - Hospital business revenue was $1,280,000,000, up 16% in constant currency [32] - Home care business revenue reached $739,900,000, an 11% increase in constant currency [32] Market Data and Key Metrics Changes - The company treated 22 million patients with its products during FY 2025 [28] - The manufacturing facility in China became fully operational, contributing to product shipments [29] Company Strategy and Development Direction - The company focuses on long-term planning, with a perspective extending beyond 15 years [6][7] - Infrastructure investments include the construction of a fifth building at the East Tamaki campus and securing land for a second campus in New Zealand [7] - The company aims to double its constant currency revenue every five to six years sustainably [57] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the impact of global geopolitics and tariffs but emphasized a long-term approach to mitigate cost increases [8][11] - The outlook for FY 2026 includes revenue expectations between $2,150,000,000 and $2,250,000, with net profit after tax projected between $390,000,000 and $440,000,000 [53] Other Important Information - The board approved a dividend of $0.0425 per share, a 2% increase over the previous year, with a payout ratio of approximately 66% [12][13] - The company is committed to ongoing investments in R&D and maintaining a prudent balance sheet [13] Q&A Session Summary Question: Why hasn't the company conducted a major investor day like Xero? - The company complies with New Zealand regulations and believes its disclosures are adequate, thus not planning to adopt the Australian remuneration report [63] Question: What are the expectations for FY 2026 underlying profit? - The company provided specific guidance for FY 2026, indicating a long-term growth trajectory despite anomalies during the COVID period [65] Question: Why hasn't the company disclosed proxy votes early? - The company prefers to have discussions without the influence of proxy votes and will disclose them after the meeting [76]